Evaluation of early treatment response and volumetric dose evaluation to target and organ at risk (small bowel/bladder/rectum) during radiation therapy of cervical cancer.
- Conditions
- Health Condition 1: null- GOODHealth Condition 2: C539- Malignant neoplasm of cervix uteri, unspecified
- Registration Number
- CTRI/2022/03/040851
- Lead Sponsor
- AIIMS
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 21
1. Biopsy proven carcinoma of cervix 2. Age : between 18-65 yrs 3. FIGO Stage IIB â?? IIIB 4. Karnofsky performance scale score 70 or above 5. Normal kidney, liver and bone marrow function 6. Patient who have given informed consent
1. Early stage cancer FIGO stage IA â??IIA 2. Metastatic patients 3. Lack of Histo-pathological proof of malignancy 4. Doubtful follow-up and /or non-compliance 5. Uncontrolled co-morbid conditions e.g. Hypertension, Diabetes Mellitus, Chronic Obstructive pulmonary disease (COPD), coronary artery disease (CAD), Severe Mental or Physical Disorder 6. Pregnancy 7. Deranged renal, liver function test 8. Patient refusing to give written informed consent 9. H/O- of previous irradiation 10. H/O-of allergy 11. Collagen vascular disease
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method a)To evaluate early treatment response in locally advanced cervical cancer treated with 3D conformal radiotherapy and image based brachytherapy <br/ ><br>b)To evaluate volumetric doses to target and OAR (rectum/bladder/small bowel) <br/ ><br>Timepoint: 1O MONTHS
- Secondary Outcome Measures
Name Time Method a)To evaluate acute haematological/bladder/bowel toxicities. <br/ ><br>b)To compare dosimetric parameter between 3D conformal radiation therapy and Volumetric Modulated Arc Therapy (VMAT) <br/ ><br>Timepoint: 10 MONTHS